Tecovirimat

From Ganfyd

Jump to: navigation, search
Tecovirimat is successfully developed for smallpox based purely on non human viral disease models. These were monkeypox and rabbitpox models. It is tolerated well in human volunteers. The dose is 600mg orally twice daily in humans.[1]. If you need it, lets hope governments have arranged stock to be available within ideally 4 days, or at least 8 days of exposure. [2]

The drug works by inhibiting p37 protein which is essential for formation and cellular egress of virions and is produced by all orthopoxviruses

References